Abstract
The plasminogen activator/plasmin system represents a key component of the proteolytic machinery underlying angiogenesis. In this work, we investigated the effect of Neovastat (Æ-941), a naturally occurring multifunctional antiangiogenic agent that is currently in Phase III clinical trials, on tissue and urokinase plasminogen activator activities. We found that in vitro, Neovastat at 100μg/ml markedly stimulates t-PA-mediated plasmin generation, while it slightly inhibits the generation of plasmin mediated by uPA. The stimulatory effect of Neovastat on t-PA activity was markedly increased by a heat treatment, resulting in a 15-fold increase in the rate of activation of plasminogen. Neovastat did not directly stimulate the activity of t-PA or plasmin towards exogenous substrates, suggesting that its effect requires the presence of plasminogen. Accordingly, kinetic analysis showed that Neovastat increases both the k cat of t-PA as well as its affinity for plasminogen by 10-fold. The stimulation of t-PA activity by Neovastat was also correlated with a direct interaction of Neovastat with plasminogen as monitored by the surface plasmon resonance technology. Overall, these results identify Neovastat as a potent stimulator of t-PA-dependent activation of plasminogen, further emphasizing its pleiotropic mechanism of action on several molecular events involved in angiogenesis.
Similar content being viewed by others
References
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31, 1995
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364, 1996
Pepper MS: Role of matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21: 1104–1117, 2001
Lijnen HR, Collen D: Mechanisms of physiological fibrinolysis. Baillière's Clin Haematol 8: 277–290, 1995
Murphy G, Gavrilovic J: Proteolysis and cell migration: Creating a path? Curr Opin Cell Biol 11: 614–621, 1999
Gyetko MR, Todd RF III, Wilkerson CC, Sitrin RG: The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93: 1380–1398, 1994
Min HY, Doyle LV, Vitt CR, Zandonella L, Stratton-Thomas JR, Shuman MA, Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428–2433, 1996
Huber D, Cramer EM, Kaufmann JE, Meda P, Massé JM, Kruithof EKO, Vischer UM: Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 99: 3637–3645, 2002
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315–328, 1994
Westphal JR, Van't Hullenaar R, Geurts-Moespot A, Sweep FCJG, Verheijen JH, Bussemakers MMG, Askaa J, Clemmensen I, Eggermont AAM, Rutter DJ, De Waal RMW: Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators. Int J Cancer 86: 760–767, 2000
Ferrier CM, Suciu S, van Geloof WL, Straatman H, Eggermont AAM, Koops HS, Kroon BBR, Lejeune FJ, Kleeberg UR, van Muijen GNP, Ruiter DJ: High t-PA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 83: 1351–1359, 2000
Chappuis PO, Dieterich B, Sciretta V, Lohse C, Bonnefoi H, Remadi S, Sappino A-P: Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 19: 2731–2738, 2001
Sawaya R, Ramo OJ, Shi ML, Mandybur G: Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74: 480–486, 1991
Reijerkerk A, Voest EE, Gebbink MFBG: No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 36: 1695–1705, 2000
Gingras D, Batist G, Béliveau R: Æ-941 (Neovastat®): A novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1: 341–347, 2001
Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E: Neovastat (Æ-941) in refractory renal cell carcinoma patients -Report of a phase II trial with two dose levels. Annals Oncol 13: 1259–1263, 2002
Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E: Æ-941 (Neovastat), a naturally occuring multifunctional antiangiogenic product in Phase III clinical trials. Semin Oncol 28: 620–625, 2001
Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Béliveau R: Matrix proteinase inhibition by Æ-941, a multifunctional antiangiogenic compound. Anticancer Res 21: 145–155, 2001
Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin M-C, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E: The antiangiogenic agent Neovastat (Æ-941) inhibits VEGF-mediated biological effects. Clin Cancer Res 8: 1242–1250, 2002
Boivin D, Gendron S, Beaulieu E, Gingras D, Béliveau R: The antiangiogenic agent Neovastat (Æ-941) induces endothelial cell apoptosis. Mol Cancer Ther 1: 795–802, 2002
Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pépin M-C, Wang T, Alaoui-Jamali MA: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19: 145–153, 2002
Dupont E, Brazeau P, Juneau C: Extracts of shark cartilage having an antiangiogenic activity and an effect on tumor progression: Process of making thereof. United States Patent, 1997
Drapier JC, Tenu JP, Lemaire G, Petit JF: Regulation of plasminogen activator secretion in mouse peritoneal macrophages. I-Role of serum studied by a new spectrophotometric assay for plasminogen activators. Biochimie 61: 463–471, 1979
Ranby M: Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 704: 461–469, 1982
Machovich R, Owen WG: Denatured proteins as cofactors for plasminogen activation. Arch Biochem Biophys 344: 343–349, 1997
Radcliffe R: A critical role of lysine residues in the stimulation of tissue plasminogen activator by denatured proteins and fibrin clots. Biochim Biophys Acta 743: 422–430, 1983
Stack S, Gonzalez-Gronow M, Pizzo SV: Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry 29: 4966–4970, 1990
Radcliffe R, Heinze T: Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: A possible additional role for plasminogen activator? Arch Biochem Biophys 211: 750–761, 1981
Kranenburg O, Bouma B, Kroon-Batenburg LMJ, Reijerkerk A, Wu Y-P, Voest EE, Gebbink MFBG: Tissue-type plasminogen activator is a multiligand cross-βstructure receptor. Curr Biol 12: 1833–1839, 2002
Hayashi S, Yokoyama I, Namii Y, Emi N, Uchida K, Takagi H: Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer. Cancer Gene Ther 6: 380–384, 1999
Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP: In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 95, 388–399, 2003
Reijerkerk A, Mosnier LO, Kranenburg O, Bouma BN, Carmeliet P, Drixler T, Meijers JC, Voest EE, Gebbink MF: Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res 1, 561–568, 2003
Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA: Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 340: 77–84, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gingras, D., Labelle, D., Nyalendo, C. et al. The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity. Invest New Drugs 22, 17–26 (2004). https://doi.org/10.1023/B:DRUG.0000006171.54078.3d
Issue Date:
DOI: https://doi.org/10.1023/B:DRUG.0000006171.54078.3d